Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription 25.08.2025 2 Am J Surg Pathol 2 BMC Cancer 1 Curr Treat Options Oncol 10 Gynecol Oncol 2 Int J Cancer 1 Int J Gynaecol Obstet 5 Int J Gynecol Pathol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. KEYHANIAN K, Busca A, Howitt B, Hammer P, et al
   Dominant Negative PTEN Alterations in Endometrial Carcinoma Are Associated With Retained Immunohistochemical PTEN Expression.
   Am J Surg Pathol. 2025 May 22. doi: 10.1097/PAS.0000000000002412.
   PubMed         Abstract available
   
   
2. KARUNADHAS NS, Catherwood M, Stringfellow H, Arora R, et al
   "Early" Clear Cell Proliferations (Clear Cell Carcinoma in Situ) in Ovarian Endometriotic Cysts: Report of a Case Series With Recommendations for Terminology.
   Am J Surg Pathol. 2025 May 6. doi: 10.1097/PAS.0000000000002415.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. PARK S, Kim H, Wee CW, Kim YS, et al
   Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204).
   BMC Cancer. 2025;25:1336.
   PubMed         Abstract available
   
   
4. APELIAN S, Hamdan A, Mohammad R, Abbas A, et al
   Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years: a national multicenter retrospective study (2017-2021).
   BMC Cancer. 2025;25:1359.
   PubMed         Abstract available
   
   

   
   Curr Treat Options Oncol

5. WANG Z, Liu Y, Yang Q
   Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation.
   Curr Treat Options Oncol. 2025 Aug 19. doi: 10.1007/s11864-025-01347.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

6. SMITH AJ, Acharya R, Ang L, Moore T, et al
   "What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer.
   Gynecol Oncol. 2025;201:118-122.
   PubMed         Abstract available
   
   
7. BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
   Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
   Gynecol Oncol. 2025;199:10-16.
   PubMed         Abstract available
   
   
8. KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
   Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
   Gynecol Oncol. 2025;199:40-46.
   PubMed         Abstract available
   
   
9. GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
   Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
   Gynecol Oncol. 2025;199:64-71.
   PubMed         Abstract available
   
   
10. GASPAR-MAIA A, Sasamoto N
    Prevention, early detection & interception: 15th biennial ovarian cancer research symposium.
    Gynecol Oncol. 2025;201:83-85.
    PubMed         Abstract available
    
    
11. ROBIN TP, Hu J, Jones BL, Patton T, et al
    Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
    Gynecol Oncol. 2025;200:175-179.
    PubMed         Abstract available
    
    
12. SOZEN H, Minareci Y, Toyran A, Tutar E, et al
    Evaluation of total retroperitoneal en-bloc resection of multivisceral-peritoneal packet (TROMP) in advanced ovarian cancer: A single-center cohort study.
    Gynecol Oncol. 2025;201:102-108.
    PubMed         Abstract available
    
    
13. ZHANG N, Porter RL
    Emerging approaches to enhance immune responses in ovarian cancer: 15th biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:97-101.
    PubMed         Abstract available
    
    
14. LANITI DD, Verma P
    State-of-the art in emerging therapeutics for ovarian cancer therapy.
    Gynecol Oncol. 2025;201:109-113.
    PubMed         Abstract available
    
    
15. SOONG TR, Islam BN, Hunt K, Nadeem A, et al
    Research is care: How patients and researchers can work together to bring the bedside back to the bench - a patient advocacy panel discussion: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:114-117.
    PubMed         Abstract available
    
    

    
    Int J Cancer

16. DAUGS K, Brandes D, Yasin L, Anwar A, et al
    Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.
    Int J Cancer. 2025 Aug 26. doi: 10.1002/ijc.70097.
    PubMed         Abstract available
    
    
17. LI H, Feng Y, Wang Z, Li X, et al
    Advances in the management of ovarian cancer liver metastasis.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
    PubMed         Abstract available
    
    

    
    Int J Gynaecol Obstet

18. ASSAF W, Qarawani A, Abboud Y, Shalabna E, et al
    Pathology results of risk-reducing salpingo-oophorectomy in BRCA1/2 carriers and long-term clinical outcomes.
    Int J Gynaecol Obstet. 2025;170:1188-1198.
    PubMed         Abstract available
    
    

    
    Int J Gynecol Pathol

19. FALLAS J, Salmon I, Maris C, Gomez Galdon M, et al
    First Case of Ovarian Metastases From a Primary Retroperitoneal Mucinous Carcinoma Associated With Teratoma, With KRAS and ERBB3 Mutations: Case Report and Literature Review.
    Int J Gynecol Pathol. 2025;44:461-465.
    PubMed         Abstract available
    
    
20. LEI L, Aisagbonhi O
    Sclerosis in Metastatic Uterine Tumor Resembling Ovarian Sex Cord Tumor: Diagnostic Dilemma Presented by Unusual Morphology.
    Int J Gynecol Pathol. 2025;44:457-460.
    PubMed         Abstract available
    
    
21. GULSEREN V, Dolanbay M, Cagli F, Daggez M, et al
    The Role of hCG Expression in Endometrial Cancer Prognosis.
    Int J Gynecol Pathol. 2025;44:445-450.
    PubMed         Abstract available
    
    
22. CHAPAGAIN U, Huecker JB, Sun L
    Morphologic Correlations With Homologous Recombination Deficiency in High-grade Serous Carcinomas.
    Int J Gynecol Pathol. 2025;44:398-406.
    PubMed         Abstract available
    
    
23. LEPE M, Mejia E, Bu Y, Hecht JL, et al
    Morphologic Characteristics Seen in High-grade Serous Ovarian Carcinoma Metastases in Postneoadjuvant Chemotherapy Resections.
    Int J Gynecol Pathol. 2025;44:407-411.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.